| Budget Amount *help |
¥26,520,000 (Direct Cost: ¥20,400,000、Indirect Cost: ¥6,120,000)
Fiscal Year 2014: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2013: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2012: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Outline of Final Research Achievements |
Oligonucleotide therapeutics, such as siRNA and antisense oligonucleotides, has attracted attention as an innovative medicine for intractable diseases that have no cure. However, it is largely unknown how oligonucleotide therapeutics is incorporated into the cell, and subsequently, transported to the target RNA. In this study, we identified some molecules which are involved in incorporation of oligonucleotides into HEK293 cells.
|
